Antiviral potential of cathelicidins

Future Microbiology

Volumn 9, Issue 1, 2014, Pages 55-73

  Barlow, Peter G ^a   Findlay, Emily Gwyer ^b   Currie, Silke M ^b   Davidson, Donald J ^b  

^a EDINBURGH NAPIER UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

adenovirus; antimicrobial peptide; cationic host defense peptide; herpes simplex virus; HIV; influenza; innate immunity; respiratory syncytial virus; vaccinia virus; virus

Indexed keywords

ANTIVIRUS AGENT; CATHELICIDIN;

ANTIVIRAL ACTIVITY; DENGUE VIRUS; DRUG MECHANISM; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOMODULATION; INFLUENZA VIRUS A; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SWINE; VACCINIA VIRUS;

ANTIVIRAL AGENTS; CATHELICIDINS; VIRUSES;

EID: 84890737050     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.135     Document Type: Review

References (192)

1. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415(6870), 389-395 (2002).
2. Bowdish DM, Davidson DJ, Hancock RE. A re-evaluation of the role of host defence peptides in mammalian immunity. Curr. Protein Pept. Sci. 6(1), 35-51(2005).
3. Semple F, Dorin Jr. Beta-defensins: Multifunctional modulators of infection, inflammation and more?. J. Innate Immun. 4(4), 337- 348 (2012).
4. Beaumont PE, Li H, Davidson DJ. LL 37: An immunomodulatory antimicrobial host defence peptide. In: Antimicrobial peptides and Innate Immunity. Hiemstra PS, Zaat Saj (Eds). Springer Basel AG, Basel, Switzerland, 97-122 (2013).
5. Pazgier M, Ericksen B, Ling M et al. Structural and functional analysis of the pro-domain of human cathelicidin, LL 37. Biochemistry 52(9), 1547-1558 (2013).
6. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J. Leukoc. Biol. 75(1), 39-48 (2004).
7. Sorensen OE, Follin P, Johnsen AH et al. Human cathelicidin, hCAP 18, is processed to the antimicrobial peptide LL 37 by extracellular cleavage with proteinase 3. Blood 97(12), 3951-3959 (2001).
8. Agerberth B, Charo J, Werr J et al. The human antimicrobial and chemotactic peptides LL 37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 96(9), 3086-3093 (2000).
9. Agerberth B, Gunne H, Odeberg J, Kogner P, Boman HG, Gudmundsson GH. FALL 39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc. Natl Acad. Sci. USA 92(1), 195-199 (1995).
10. Wang G. Structures of human host defense cathelicidin LL 37 and its smallest antimicrobial peptide KR-12 in lipid micelles. J. Biol. Chem. 283(47), 32637-32643 (2008).
11. Murakami M, Lopez-Garcia B, Braff M, Dorschner RA, Gallo RL. Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J. Immunol. 172(5), 3070-3077 (2004).
12. Yamasaki K, Schauber J, Coda A et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J. 20(12), 2068-2080 (2006).
13. Sorensen OE, Gram L, Johnsen AH et al. Processing of seminal plasma hCAP 18 to ALL 38 by gastricsin: A novel mechanism of generating antimicrobial peptides in vagina. J. Biol. Chem. 278(31), 28540-28546 (2003).
14. Braff MH, Hawkins MA, Nardo AD et al. Structure-function relationships among human cathelicidin peptides: Dissociation of antimicrobial properties from host immunostimulatory activities. J. Immunol. 174(7), 4271-4278 (2005).
15. Wang G, Elliott M, Cogen AL, Ezell EL, Gallo RL, Hancock RE. Structure, dynamics, and antimicrobial and immune modulatory activities of human LL 23 and its single-residue variants mutated on the basis of homologous primate cathelicidins. Biochemistry 51(2), 653-664 (2012).
16. Li HN, Barlow PG, Bylund J et al. Secondary necrosis of apoptotic neutrophils induced by the human cathelicidin LL 37 is not proinflammatory to phagocytosing macrophages. J. Leukoc. Biol. 86(4), 891-902 (2009).
17. Frohm M, Agerberth B, Ahangari G et al. The expression of the gene coding for the antibacterial peptide LL 37 is induced in human keratinocytes during inflammatory disorders. J. Biol. Chem. 272(24), 15258-15263 (1997).
18. Erdag G, Morgan Jr. Interleukin-1alpha and interleukin-6 enhance the antibacterial properties of cultured composite keratinocyte grafts. Ann. Surg. 235(1), 113-124 (2002).
19. Nell MJ, Sandra Tjabringa G, Vonk MJ, Hiemstra PS, Grote JJ. Bacterial products increase expression of the human cathelicidin hCAP 18/LL 37 in cultured human sinus epithelial cells. FEMS Immunol. Med. Microbiol. 42(2), 225-231 (2004).
20. Dorschner RA, Pestonjamasp VK, Tamakuwala S et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A streptococcus. J. Invest. Dermatol. 117(1), 91-97 (2001).
21. Wang TT, Nestel FP, Bourdeau V et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 173(5), 2909-2912 (2004).
22. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 19(9), 1067-1077 (2005).
23. Martineau AR, Wilkinson KA, Newton SM et al. IFN-gamma-And TNF-independent vitamin D-inducible human suppression of mycobacteria: The role of cathelicidin LL 37. J. Immunol. 178(11), 7190-7198 (2007).
24. Yim S, Dhawan P, Ragunath C, Christakos S, Diamond G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25- dihydroxyvitamin D(3). J. Cyst. Fibros. 6(6), 403-410 (2007).
25. Muehleisen B, Bikle DD, Aguilera C et al. PTH/PTHrP and vitamin D control antimicrobial peptide expression and susceptibility to bacterial skin infection. Sci. Transl. Med. 4(135), 135ra166 (2012).
26. van der Does AM, Bergman P, Agerberth B, Lindbom L. Induction of the human cathelicidin LL 37 as a novel treatment against bacterial infections. J. Leukoc. Biol. 92(4), 735-742 (2012).
27. Sorensen O, Arnljots K, Cowland JB, Bainton DF, Borregaard N. The human antibacterial cathelicidin, hCAP 18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 90(7), 2796-2803 (1997).
28. Schaller-Bals S, Schulze A, Bals R. Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection. Am. J. Respir. Crit. Care Med. 165(7), 992-995 (2002).
29. Chen CI, Schaller-Bals S, Paul KP, Wahn U, Bals R. Beta-defensins and LL 37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. J. Cyst. Fibros. 3(1), 45-50 (2004).
30. Sun J, Dahlen B, Agerberth B, Haeggstrom JZ. The antimicrobial peptide LL 37 induces synthesis and release of cysteinyl leukotrienes from human eosinophils - implications for asthma. Allergy 68(3), 304-311 (2013).
31. Ong PY, Ohtake T, Brandt C et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347(15), 1151-1160 (2002).
32. Lande R, Gregorio J, Facchinetti V et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449(7162), 564-569 (2007).
33. Putsep K, Carlsson G, Boman HG, Andersson M. Deficiency of antibacterial peptides in patients with morbus Kostmann: An observation study. Lancet 360(9340), 1144-1149 (2002).
34. Schauber J, Gallo RL. Antimicrobial peptides and the skin immune defense system. J. Allergy Clin. Immunol. 122(2), 261-266 (2008).
35. Bals R, Weiner DJ, Moscioni AD, Meegalla RL, Wilson JM. Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect. Immun. 67(11), 6084-6089 (1999).
36. Wang Y, Agerberth B, Lothgren A, Almstedt A, Johansson J. Apolipoprotein A-I binds and inhibits the human antibacterial/cytotoxic peptide LL 37. J. Biol. Chem. 273(50), 33115-33118 (1998).
37. Weiner DJ, Bucki R, Janmey PA. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-Actin bundles and restored by gelsolin. Am. J. Respir. Cell. Mol. Biol. 28(6), 738-745 (2003).
38. Yang D, Chen Q, Schmidt AP et al. LL 37, the neutrophil granule-And epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192(7), 1069-1074 (2000).
39. Singh D, Qi R, Jordan JL, San Mateo L, Kao CC. The human antimicrobial peptide LL 37, but not the mouse ortholog, mCRAMP, can stimulate signaling by poly(I:C) through a FPRL1-dependent pathway. J. Biol. Chem. 12, 8258-8268 (2013).
40. Wantha S, Alard JE, Megens RT et al. Neutrophil-derived cathelicidin promotes adhesion of classical monocytes. Circ. Res. 112(5), 792-801 (2013).
41. Zhang Z, Cherryholmes G, Chang F, Rose DM, Schraufstatter I, Shively JE. Evidence that cathelicidin peptide LL 37 may act as a functional ligand for CXCR2 on human neutrophils. Eur. J. Immunol. 39(11), 3181-3194 (2009).
42. Subramanian H, Gupta K, Guo Q, Price R, Ali H. MAS-related gene X2 (MrgX2) is a novel G protein coupled receptor for the antimicrobial peptide LL 37 in human mast cells: Resistance to receptor phosphorylation, desensitization and internalization. J. Biol. Chem. 286(52), 44739-44749 (2011).
43. Elssner A, Duncan M, Gavrilin M, Wewers MD. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1beta processing and release. J. Immunol. 172(8), 4987-4994 (2004).
44. Mookherjee N, Lippert DN, Hamill P et al. Intracellular receptor for human host defense peptide LL 37 in monocytes. J. Immunol. 183(4), 2688-2696 (2009).
45. Tomasinsig L, Pizzirani C, Skerlavaj B et al. The human cathelicidin LL 37 modulates the activities of the P2X7 receptor in a structure-dependent manner. J. Biol. Chem. 283(45), 30471-30481 (2008).
46. Barlow PG, Svoboda P, Mackellar A et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL 37. PLoS ONE 6(10), e25333 (2011).
47. Gallo RL, Kim KJ, Bernfield M et al. Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J. Biol. Chem. 272(20), 13088-13093 (1997).
48. Pestonjamasp VK, Huttner KH, Gallo RL. Processing site and gene structure for the murine antimicrobial peptide CRAMP. Peptides 22(10), 1643-1650 (2001).
49. Yu K, Park K, Kang SW, Shin SY, Hahm KS, Kim Y. Solution structure of a cathelicidin-derived antimicrobial peptide, CRAMP as determined by NMR spectroscopy. J. Pept. Res. 60(1), 1-9 (2002).
50. Nizet V, Ohtake T, Lauth X et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414(6862), 454-457 (2001).
51. Iimura M, Gallo RL, Hase K, Miyamoto Y, Eckmann L, Kagnoff MF. Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens. J. Immunol. 174(8), 4901-4907 (2005).
52. Chromek M, Slamova Z, Bergman P et al. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat. Med. 12(6), 636-641 (2006).
53. Kovach MA, Ballinger MN, Newstead MW et al. Cathelicidin-related antimicrobial Peptide is required for effective lung mucosal immunity in Gram-negative bacterial pneumonia. J. Immunol. 189(1), 304-311 (2012).
54. Braff MH, Jones AL, Skerrett SJ, Rubens CE. Staphylococcus aureus exploits cathelicidin antimicrobial peptides produced during early pneumonia to promote staphylokinase-dependent fibrinolysis. J. Infect. Dis. 195(9), 1365-1372 (2007).
55. Alalwani MS, Sierigk J, Herr C et al. The antimicrobial peptide LL 37 modulates the inflammatory and host defense response of human neutrophils. Eur. J. Immunol. 40(4), 1118-1126 (2010).
56. Huang LC, Reins RY, Gallo RL, McDermott AM. Cathelicidin-deficient (Cnlp -/-) mice show increased susceptibility to Pseudomonas aeruginosa keratitis. Invest. Ophthalmol. Vis. Sci. 48(10), 4498-4508 (2007).
57. Kurosaka K, Chen Q, Yarovinsky F, Oppenheim JJ, Yang D. Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. J. Immunol. 174(10), 6257-6265 (2005).
58. Howell MD, Jones JF, Kisich KO, Streib JE, Gallo RL, Leung DY. Selective killing of vaccinia virus by LL 37: Implications for eczema vaccinatum. J. Immunol. 172(3), 1763-1767 (2004).
59. Sang Y, Blecha F. Porcine host defense peptides: Expanding repertoire and functions. Dev. Comp. Immunol. 33(3), 334-343 (2009).
60. Kokryakov VN, Harwig SS, Panyutich EA et al. Protegrins: Leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Lett. 327(2), 231-236 (1993).
61. Panyutich A, Shi J, Boutz PL, Zhao C, Ganz T. Porcine polymorphonuclear leukocytes generate extracellular microbicidal activity by elastase-mediated activation of secreted proprotegrins. Infect. Immun. 65(3), 978-985 (1997).
62. Vivcharuk V, Kaznessis YN. Thermodynamic analysis of protegrin-1 insertion and permeation through a lipid bilayer. J. Phys. Chem. B. 115(49), 14704-14712 (2011).
63. Bolintineanu DS, Vivcharuk V, Kaznessis YN. Multiscale models of the antimicrobial peptide protegrin-1 on Gram-negative bacteria membranes. Int. J. Mol. Sci. 13(9), 11000-11011 (2012).
64. Mangoni ME, Aumelas A, Charnet P et al. Change in membrane permeability induced by protegrin 1: Implication of disulphide bridges for pore formation. FEBS Lett. 383(1-2), 93-98 (1996).
65. Ding L, Yang L, Weiss TM, Waring AJ, Lehrer RI, Huang HW. Interaction of antimicrobial peptides with lipopolysaccharides. Biochemistry 42(42), 12251-12259 (2003).
66. Zughaier SM, Shafer WM, Stephens DS. Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages. Cell Microbiol. 7(9), 1251-1262 (2005).
67. Harwig SS, Waring A, Yang HJ, Cho Y, Tan L, Lehrer RI. Intramolecular disulfide bonds enhance the antimicrobial and lytic activities of protegrins at physiological sodium chloride concentrations. Eur. J. Biochem. 240(2), 352-357 (1996).
68. Yasin B, Harwig SS, Lehrer RI, Wagar EA. Susceptibility of Chlamydia trachomatis to protegrins and defensins. Infect. Immun. 64(3), 709-713 (1996).
69. Yasin B, Lehrer RI, Harwig SS, Wagar EA. Protegrins: Structural requirements for inactivating elementary bodies of Chlamydia trachomatis. Infect. Immun. 64(11), 4863-4866 (1996).
70. Miyakawa Y, Ratnakar P, Rao AG et al. In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis. Infect. Immun. 64(3), 926-932 (1996).
71. Qu XD, Harwig SS, Oren AM, Shafer WM, Lehrer RI. Susceptibility of Neisseria gonorrhoeae to protegrins. Infect. Immun. 64(4), 1240-1245 (1996).
72. Steinstraesser L, Klein RD, Aminlari A et al. Protegrin-1 enhances bacterial killing in thermally injured skin. Crit. Care Med. 29(7), 1431-1437 (2001).
73. Cho Y, Turner JS, Dinh NN, Lehrer RI. Activity of protegrins against yeast-phase Candida albicans. Infect. Immun. 66(6), 2486-2493 (1998).
74. Cheung QC, Turner PV, Song C et al. Enhanced resistance to bacterial infection in protegrin-1 transgenic mice. Antimicrob. Agents Chemother. 52(5), 1812-1819 (2008).
75. Ceccarelli AV, Cole AM, Park AK, Tahk S, Yoshioka D, Ganz T. Therapeutic effect of a pig-derived peptide antibiotic on porcine wound infections. Comp. Med. 51(1), 75-79 (2001).
76. Koszalka P, Kamysz E, Wejda M, Kamysz W, Bigda J. Antitumor activity of antimicrobial peptides against U937 histiocytic cell line. Acta Biochim. Polon. 58(1), 111-117 (2011).
77. Steinstraesser L, Hauk J, Al-Benna S et al. Genotoxic and cytotoxic activity of host defense peptides against human soft tissue sarcoma in an in vitro model. Drug Chem. Toxicol. 35(1), 96-103 (2012).
78. Storici P, Scocchi M, Tossi A, Gennaro R, Zanetti M. Chemical synthesis and biological activity of a novel antibacterial peptide deduced from a pig myeloid cDNA. FEBS Lett. 337(3), 303-307 (1994).
79. Tossi A, Scocchi M, Zanetti M, Storici P, Gennaro R. PMAP 37, a novel antibacterial peptide from pig myeloid cells. cDNA cloning, chemical synthesis and activity. Eur. J. Biochem. 228(3), 941-946 (1995).
80. Park Y, Jang SH, Lee DG, Hahm KS. Antinematodal effect of antimicrobial peptide, PMAP 23, isolated from porcine myeloid against Caenorhabditis elegans. J. Pept. Sci. 10(5), 304-311 (2004).
81. Lee DG, Kim PI, Park Y et al. Design of novel peptide analogs with potent fungicidal activity, based on PMAP 23 antimicrobial peptide isolated from porcine myeloid. Biochem. Biophys. Res. Commun. 293(1), 231-238 (2002).
82. Ramanathan B, Wu H, Ross CR, Blecha F. PR 39, a porcine antimicrobial peptide, inhibits apoptosis: Involvement of caspase-3. Dev. Comp. Immunol. 28(2), 163-169 (2004).
83. Li J, Post M, Volk R et al. PR39, a peptide regulator of angiogenesis. Nat. Med. 6(1), 49-55 (2000).
84. Agerberth B, Lee JY, Bergman T et al. Amino acid sequence of PR 39. Isolation from pig intestine of a new member of the family of proline-Arginine-rich antibacterial peptides. Eur. J. Biochem. 202(3), 849-854 (1991).
85. Djanani A, Mosheimer B, Kaneider NC et al. Heparan sulfate proteoglycan-dependent neutrophil chemotaxis toward PR 39 cathelicidin. J. Inflamm. (Lond.) 3, 14 (2006).
86. Shinnar AE, Butler KL, Park HJ. Cathelicidin family of antimicrobial peptides: Proteolytic processing and protease resistance. Bioorgan. Chem. 31(6), 425-436 (2003).
87. Gennaro R, Zanetti M, Benincasa M, Podda E, Miani M. Pro-rich antimicrobial peptides from animals: Structure, biological functions and mechanism of action. Curr. Pharm. Des. 8(9), 763-778 (2002).
88. Vunnam S, Juvvadi P, Merrifield RB. Synthesis and antibacterial action of cecropin and proline-Arginine-rich peptides from pig intestine. J. Pept. Res. 49(1), 59-66 (1997).
89. Wang Y, Johansson J, Griffiths WJ. Characterisation of variant forms of prophenin: Mechanistic aspects of the fragmentation of proline-rich peptides. Rapid. Commun. Mass Spectromet. RCM 14(23), 2182-2202 (2000).
90. Wang Y, Walter G, Herting E, Agerberth B, Johansson J. Antibacterial activities of the cathelicidins prophenin (residues 62 to 79) and LL 37 in the presence of a lung surfactant preparation. Antimicrob. Agents Chemother. 48(6), 2097-2100 (2004).
91. Tomasinsig L, Zanetti M. The cathelicidins - structure, function and evolution. Curr. Protein Pept. Sci. 6(1), 23-34 (2005).
92. Skerlavaj B, Scocchi M, Gennaro R, Risso A, Zanetti M. Structural and functional analysis of horse cathelicidin peptides. Antimicrob. Agents Chemother. 45(3), 715-722 (2001).
93. Bals R, Lang C, Weiner DJ, Vogelmeier C, Welsch U, Wilson JM. Rhesus monkey (Macaca mulatta) mucosal antimicrobial peptides are close homologues of human molecules. Clin. Diagn. Lab. Immunol. 8(2), 370-375 (2001).
94. Larrick JW, Morgan JG, Palings I, Hirata M, Yen MH. Complementary DNA sequence of rabbit CAP18 -A unique lipopolysaccharide binding protein. Biochem. Biophys. Res. Commun. 179(1), 170-175 (1991).
95. Bagella L, Scocchi M, Zanetti M. cDNA sequences of three sheep myeloid cathelicidins. FEBS Lett. 376(3), 225-228 (1995).
96. Chang CI, Zhang YA, Zou J, Nie P, Secombes CJ. Two cathelicidin genes are present in both rainbow trout (Oncorhynchus mykiss) and Atlantic salmon (Salmo salar). Antimicrob. Agents Chemother. 50(1), 185-195 (2006).
97. Gennaro R, Skerlavaj B, Romeo D. Purification, composition, and activity of two bactenecins, antibacterial peptides of bovine neutrophils. Infect. Immun. 57(10), 3142-3146 (1989).
98. Frank RW, Gennaro R, Schneider K, Przybylski M, Romeo D. Amino acid sequences of two proline-rich bactenecins. Antimicrobial peptides of bovine neutrophils. J. Biol. Chem. 265(31), 18871-18874 (1990).
99. Del Sal G, Storici P, Schneider C, Romeo D, Zanetti M. cDNA cloning of the neutrophil bactericidal peptide indolicidin. Biochem. Biophys. Res. Commun. 187(1), 467-472 (1992).
100. Storici P, Del Sal G, Schneider C, Zanetti M. cDNA sequence analysis of an antibiotic dodecapeptide from neutrophils. FEBS Lett. 314(2), 187-190 (1992).
101. Scocchi M, Wang S, Zanetti M. Structural organization of the bovine cathelicidin gene family and identification of a novel member. FEBS Lett. 417(3), 311-315 (1997).
102. Selsted ME, Novotny MJ, Morris WL, Tang YQ, Smith W, Cullor JS. Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils. J. Biol. Chem. 267(7), 4292-4295 (1992).
103. Skerlavaj B, Romeo D, Gennaro R. Rapid membrane permeabilization and inhibition of vital functions of Gram-negative bacteria by bactenecins. Infect. Immun. 58(11), 3724-3730 (1990).
104. Risso A, Braidot E, Sordano MC et al. BMAP 28, an antibiotic peptide of innate immunity, induces cell death through opening of the mitochondrial permeability transition pore. Mol. Cell Biol. 22(6), 1926-1935 (2002).
105. Carryn S, Schaefer DA, Imboden M, Homan EJ, Bremel RD, Riggs MW. Phospholipases and cationic peptides inhibit Cryptosporidium parvum sporozoite infectivity by parasiticidal and non-parasiticidal mechanisms. J. Parasitol. 98(1), 199-204 (2012).
106. Pompilio A, Scocchi M, Pomponio S et al. Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients. Peptides 32(9), 1807-1814 (2011).
107. D'Este F, Tomasinsig L, Skerlavaj B, Zanetti M. Modulation of cytokine gene expression by cathelicidin BMAP 28 in LPS-stimulated and -unstimulated macrophages. Immunobiology 217(10), 962-971 (2012).
108. Lynn MA, Kindrachuk J, Marr AK et al. Effect of BMAP 28 antimicrobial peptides on Leishmania major promastigote and amastigote growth: Role of leishmanolysin in parasite survival. PLoS Negl. Trop Dis. 5(5), e1141 (2011).
109. Giacometti A, Cirioni O, Ghiselli R et al. The antimicrobial peptide BMAP 28 reduces lethality in mouse models of staphylococcal sepsis. Crit. Care Med. 32(12), 2485-2490 (2004).
110. Bowdish DM, Davidson DJ, Scott MG, Hancock RE. Immunomodulatory activities of small host defense peptides. Antimicrob. Agents Chemother. 49(5), 1727-1732 (2005).
111. Gwyer Findlay E, Currie SM, Davidson DJ. Cationic host defence peptides: Potential as antiviral therapeutics. BioDrugs 27(5), 479-493 (2013).
112. Grabenstein JD, Winkenwerder W Jr. US military smallpox vaccination program experience. JAMA 289(24), 3278-3282 (2003).
113. Howell MD, Gallo RL, Boguniewicz M et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 24(3), 341-348 (2006).
114. Dean RE, O'Brien LM, Thwaite JE, Fox MA, Atkins H, Ulaeto DO. A carpet-based mechanism for direct antimicrobial peptide activity against vaccinia virus membranes. Peptides 31(11), 1966-1972 (2010).
115. Nair H, Nokes DJ, Gessner BD et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-Analysis. Lancet 375(9725), 1545-1555 (2010).
116. Krishnamoorthy N, Khare A, Oriss TB et al. Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma. Nat. Med. 18(10), 1525-1530 (2012).
117. Tregoning JS, Schwarze J. Respiratory viral infections in infants: Causes, clinical symptoms, virology, and immunology. Clin. Microbiol. Rev. 23(1), 74-98 (2010).
118. Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive vitamin D to its active form: Potential effects on host defense. J. Immunol. 181(10), 7090-7099 (2008).
119. Mansbach JM, Piedra PA, Borregaard N et al. Serum cathelicidin level is associated with viral etiology and severity of bronchiolitis. J. Allergy Clin. Immunol. 130(4), 1007.e1-1008.e1 (2012).
120. Currie S, Gwyer Findlay E, McHugh B et al. The human cathelicidin LL 37 has antiviral properties against respiratory syncytial virus. PLoS ONE 8(8), e73659 (2013).
121. Mook P, Pebody R, Zhao H et al. Surveillance of influenza and other respiratory viruses in the United Kingdom. Health Protect. Rep. 2(41), S1-S11 (2008).
122. Dawood FS, Iuliano AD, Reed C et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: A modelling study. Lancet Infect. Dis. 12(9), 687-695 (2012).
123. Sabetta JR, DePetrillo P, Cipriani RJ, Smardin J, Burns LA, Landry ML. Serum 25-hydroxyvitamin D and the incidence of acute viral respiratory tract infections in healthy adults. PLoS ONE 5(6), e11088 (2010).
124. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am. J. Clin. Nutr. 91(5), 1255-1260 (2010).
125. Tripathi S, Tecle T, Verma A, Crouch E, White M, Hartshorn KL. The human cathelicidin LL 37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins. J. Gen. Virol. 94(Pt 1), 40-49 (2013).
126. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb. Perspect. Med. 2(4), a007161 (2012).
127. Tamamura H, Murakami T, Horiuchi S et al. Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity. Chem. Pharm. Bull. 43(5), 853-858 (1995).
128. Steinstraesser L, Tippler B, Mertens J et al. Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides. Retrovirology 2, 2 (2005).
129. Bergman P, Walter-Jallow L, Broliden K, Agerberth B, Soderlund J. The antimicrobial peptide LL 37 inhibits HIV-1 replication. Curr. HIV Res. 5(4), 410-415 (2007).
130. Wang G, Watson KM, Buckheit RW Jr. Anti human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins. Antimicrob. Agents Chemother. 52(9), 3438-3440 (2008).
131. Wong JH, Legowska A, Rolka K et al. Effects of cathelicidin and its fragments on three key enzymes of HIV-1. Peptides 32(6), 1117-1122 (2011).
132. Robinson WE Jr, McDougall B, Tran D, Selsted ME. Anti-HIV-1 activity of indolicidin, an antimicrobial peptide from neutrophils. J. Leukoc. Biol. 63(1), 94-100 (1998).
133. Malm J, Sorensen O, Persson T et al. The human cationic antimicrobial protein (hCAP 18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. Infect. Immun. 68(7), 4297-4302 (2000).
134. Levinson P, Kaul R, Kimani J et al. Levels of innate immune factors in genital fluids: Association of alpha defensins and LL 37 with genital infections and increased HIV acquisition. AIDS 23(3), 309-317 (2009).
135. Levinson P, Choi RY, Cole AL et al. HIV neutralizing activity of cationic polypeptides in cervicovaginal secretions of women in HIV-serodiscordant relationships. PLoS ONE 7(2), e31996 (2012).
136. Daher KA, Selsted ME, Lehrer RI. Direct inactivation of viruses by human granulocyte defensins. J. Virol. 60(3), 1068-1074 (1986).
137. Gordon YJ, Huang LC, Romanowski EG, Yates KA, Proske RJ, McDermott AM. Human cathelicidin (LL 37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr. Eye Res. 30(5), 385-394 (2005).
138. Yasin B, Pang M, Turner JS et al. Evaluation of the inactivation of infectious herpes simplex virus by host-defense peptides. Eur. J. Clin. Microbiol. Infect. Dis. 19(3), 187-194 (2000).
139. Benincasa M, Skerlavaj B, Gennaro R, Pellegrini A, Zanetti M. In vitro and in vivo antimicrobial activity of two alpha helical cathelicidin peptides and of their synthetic analogs. Peptides 24(11), 1723-1731 (2003).
140. Albiol Matanic VC, Castilla V. Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. Int. J. Antimicrob. Agents 23(4), 382-389 (2004).
141. Rothan HA, Abdulrahman AY, Sasikumer PG, Othman S, Rahman NA, Yusof R. Protegrin-1 inhibits dengue NS2B-NS3 serine protease and viral replication in MK2 cells. J. Biomed. Biotechnol. 2012, 251482 (2012).
142. Smith JG, Silvestry M, Lindert S, Lu W, Nemerow GR, Stewart PL. Insight into the mechanisms of adenovirus capsid disassembly from studies of defensin neutralization. PLoS Pathog. 6(6), e1000959 (2010).
143. Lee SB, Li B, Jin S, Daniell H. Expression and characterization of antimicrobial peptides retrocyclin-101 and protegrin-1 in chloroplasts to control viral and bacterial infections. Plant. Biotechnol. J. 9(1), 100-115 (2011).
144. Lau YE, Rozek A, Scott MG, Goosney DL, Davidson DJ, Hancock RE. Interaction and cellular localization of the human host defense peptide LL 37 with lung epithelial cells. Infect. Immun. 73(1), 583-591 (2005).
145. Kota S, Sabbah A, Chang TH et al. Role of human beta-defensin-2 during tumor necrosis factor-Alpha/NF-kappaB-mediated innate antiviral response against human respiratory syncytial virus. J. Biol. Chem. 283(33), 22417-22429 (2008).
146. Leikina E, Delanoe-Ayari H, Melikov K et al. Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat. Immunol. 6(10), 995-1001 (2005).
147. Scott MG, Davidson DJ, Gold MR, Bowdish DM, Hancock RE. The human antimicrobial peptide LL 37 is a multifunctional modulator of innate immune responses. J. Immunol. 169(7), 3883-3891 (2002).
148. Mookherjee N, Brown KL, Bowdish DM et al. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL 37. J. Immunol. 176(4), 2455-2464 (2006).
149. Molhoek EM, den Hertog AL, de Vries AM et al. Structure-function relationship of the human antimicrobial peptide LL 37 and LL 37 fragments in the modulation of TLR responses. Biol. Chem. 390(4), 295-303 (2009).
150. Lai Y, Adhikarakunnathu S, Bhardwaj K et al. LL37 and cationic peptides enhance TLR3 signaling by viral double-stranded RNAs. PLoS ONE 6(10), e26632 (2011).
151. Filewod NC, Pistolic J, Hancock RE. Low concentrations of LL 37 alter IL-8 production by keratinocytes and bronchial epithelial cells in response to proinflammatory stimuli. FEMS Immunol. Med. Microbiol. 56(3), 233-240 (2009).
152. Hasan M, Ruksznis C, Wang Y, Leifer CA. Antimicrobial peptides inhibit polyinosinic-polycytidylic acid-induced immune responses. J. Immunol. 187(11), 5653-5659 (2011).
153. Kawai T, Akira S. The role of pattern recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 11(5), 373-384 (2010).
154. Xagorari A, Chlichlia K. Toll-like receptors and viruses: Induction of innate antiviral immune responses. Open. Microbiol. J. 2, 49-59 (2008).
155. Ganguly D, Chamilos G, Lande R et al. Self-RNA-Antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J. Exp. Med. 206(9), 1983-1994 (2009).
156. Sandgren S, Wittrup A, Cheng F et al. The human antimicrobial peptide LL 37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. J. Biol. Chem. 279(17), 17951-17956 (2004).
157. Chamilos G, Gregorio J, Meller S et al. Cytosolic sensing of extracellular self-DNA transported into monocytes by the antimicrobial peptide LL37. Blood 120(18), 3699-3707 (2012).
158. Morizane S, Yamasaki K, Muhleisen B et al. Cathelicidin antimicrobial peptide LL 37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J. Invest. Dermatol. 132(1), 135-143 (2011).
159. Zheng Y, Niyonsaba F, Ushio H et al. Cathelicidin LL 37 induces the generation of reactive oxygen species and release of human alpha-defensins from neutrophils. Br. J. Dermatol. 157(6), 1124-1131 (2007).
160. Barlow PG, Beaumont PE, Cosseau C et al. The human cathelicidin LL 37 preferentially promotes apoptosis of infected airway epithelium. Am. J. Respir. Cell Mol. Biol. 43(6), 692-702 (2010).
161. Davidson DJ, Currie AJ, Reid GS et al. The cationic antimicrobial peptide LL 37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J. Immunol. 172(2), 1146-1156 (2004).
162. Nguyen TX, Cole AM, Lehrer RI. Evolution of primate theta-defensins: A serpentine path to a sweet tooth. Peptides 24(11), 1647-1654 (2003).
163. Wohlford-Lenane CL, Meyerholz DK, Perlman S et al. Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease. J. Virol. 83(21), 11385-11390 (2009).
164. Scott MG, Dullaghan E, Mookherjee N et al. An anti-infective peptide that selectively modulates the innate immune response. Nat. Biotechnol. 25(4), 465-472 (2007).
165. Achtman AH, Pilat S, Law CW et al. Effective adjunctive therapy by an innate defense regulatory peptide in a preclinical model of severe malaria. Sci. Transl. Med. 4(135), 135ra164 (2012).
166. Rivas-Santiago B, Castañeda-Delgado JE, Rivas Santiago CE et al. Ability of innate defence regulator peptides IDR-1002, IDR-HH2 and IDR-1018 to protect against mycobacterium tuberculosis infections in animal models. PLoS ONE 8(3), e59119 (2013).
167. Kahlenberg JM, Carmona-Rivera C, Smith CK, Kaplan MJ. Neutrophil extracellular trap-Associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J. Immunol. 190(3), 1217-1226 (2013).
168. Nagaoka I, Hirota S, Niyonsaba F et al. Cathelicidin family of
169. Tjabringa GS, Aarbiou J, Ninaber DK et al. The antimicrobial peptide LL 37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J. Immunol. 171(12), 6690-6696 (2003).
170. Rosenfeld Y, Papo N, Shai Y. Endotoxin (LPS) neutralization by innate immunity host-defense peptides: Peptides' properties and plausible modes of action. J. Biol. Chem. 281(3), 1636-1643 (2006).
171. Yu J, Mookherjee N, Wee K et al. Host defense peptide LL 37, in synergy with inflammatory mediator IL-1beta, augments immune responses by multiple pathways. J. Immunol. 179(11), 7684-7691 (2007).
172. An LL, Yang YH, Ma XT et al. LL 37 enhances adaptive antitumor immune response in a murine model when genetically fused with M-CSFR(J6-1) DNA vaccine. Leuk. Res. 29(5), 535-543 (2005).
173. Bandholtz L, Ekman GJ, Vilhelmsson M et al. Antimicrobial peptide LL 37 internalized by immature human dendritic cells alters their phenotype. Scand. J. Immunol. 63(6), 410-419 (2006).
174. Niyonsaba F, Iwabuchi K, Someya A et al. A cathelicidin family of human antibacterial peptide LL 37 induces mast cell chemotaxis. Immunology 106(1), 20-26 (2002).
175. Tjabringa GS, Ninaber DK, Drijfhout JW, Rabe KF, Hiemstra PS. Human cathelicidin LL 37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. Int. Arch. Allergy Immunol. 140(2), 103-112 (2006).
176. Soehnlein O, Zernecke A, Eriksson EE et al. Neutrophil secretion products pave the way for inflammatory monocytes. Blood 112(4), 1461-1471 (2008).
177. Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I. Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL 37 on histamine release and prostaglandin D(2) production from mast cells. Eur. J. Immunol. 31(4), 1066-1075 (2001).
178. Lau YE, Bowdish DM, Cosseau C, Hancock RE, Davidson DJ. Apoptosis of airway epithelial cells: Human serum sensitive induction by the cathelicidin LL 37. Am. J. Respirat. Cell Mol. Biol. 34(4), 399-409 (2006).
179. Barlow PG, Li Y, Wilkinson TS et al. The human cationic host defense peptide LL 37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system. J. Leukoc. Biol. 80(3), 509-520 (2006).
180. Nagaoka I, Tamura H, Hirata M. An antimicrobial cathelicidin peptide, human CAP18/LL 37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7. J. Immunol. 176(5), 3044-3052 (2006).
181. Yuk JM, Shin DM, Lee HM et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe. 6(3), 231-243 (2009).
182. Zhang Z, Cherryholmes G, Shively JE. Neutrophil secondary necrosis is induced by LL 37 derived from cathelicidin. J. Leukoc. Biol. 84(3), 780-788 (2008).
183. Bjorstad A, Askarieh G, Brown KL et al. The host defense peptide LL 37 selectively permeabilizes apoptotic leukocytes. Antimicrob. Agents Chemother. 53(3), 1027-1038 (2009).
184. Mader JS, Ewen C, Hancock RE, Bleackley RC. The human cathelicidin, LL 37, induces granzyme-mediated apoptosis in regulatory T cells. J. Immunother. 34(3), 229-235 (2011).
185. Mader JS, Marcet-Palacios M, Hancock RE, Bleackley RC. The human cathelicidin, LL 37, induces granzyme-mediated apoptosis in cytotoxic T lymphocytes. Exp. Cell Res. 317(4), 531-538 (2011).
186. Koczulla R, von Degenfeld G, Kupatt C et al. An angiogenic role for the human peptide antibiotic LL 37/hCAP 18. J. Clin. Invest. 111(11), 1665-1672 (2003).
187. Yamasaki K, Di Nardo A, Bardan A et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat. Med. 13(8), 975-980 (2007).
188. Heilborn JD, Nilsson MF, Kratz G et al. The cathelicidin anti-microbial peptide LL 37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J. Invest. Dermatol. 120(3), 379-389 (2003).
189. Shaykhiev R, Beisswenger C, Kaendler K et al. The human endogenous antibiotic LL 37 stimulates airway epithelial cell proliferation and wound closure. Am. J. Physiol. Lung Cell Mol. Physiol. 289(5), L842-L848 (2005).
190. Carretero M, Escamez MJ, Garcia M et al. In vitro and in vivo wound healing-promoting activities of human cathelicidin LL 37. J. Invest. Dermatol. 128(1), 223-236 (2008).
191. Wu WK, Wang G, Coffelt SB et al. Emerging roles of the host defense peptide LL 37 in human cancer and its potential therapeutic applications. Int. J. Cancer 127(8), 1741-1747 (2010).
192. Soehnlein O, Wantha S, Simsekyilmaz S et al. Neutrophil-derived cathelicidin protects from neointimal hyperplasia. Sci. Transl. Med. 3(103), 103ra198 (2011).